The mission of FOLIGO is to develop and commercialize early stage molecular-based DNA therapeutics and diagnostics to improve standard treatment practices for women suffering from ovarian cancers.  FOLIGO’s therapeutics are designed to decrease tumor burden and metastatic disease while continuing to be safer, less toxic, and less debilitating than other therapeutics on the market.  The diagnostics provide clinicians with tools to identify most effective treatment.  FOLIGO aims to provide efficacious and cost effect therapeutics and diagnostics that will impact positively on patient longevity and quality of life.